Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 12, Number 5—May 2006
Tuberculosis Special Section

Mycobacterium tuberculosis and Rifampin Resistance, United Kingdom

I-Ching Sam*1, Francis Drobniewski*Comments to Author , Philip More*, Melanie Kemp*, and Timothy Brown*
Author affiliations: *Health Protection Agency, London, United Kingdom

Main Article

Table 6

Results of LiPA in detecting rifampin resistance in clinical specimens in which MTBC was correctly identified and cultured, stratified by history of antituberculous treatment*

Treatment history No. positive/no. tested (%)
Concordance Sensitivity Specificity PPV NPV
Current or within 3 mo 46/48 (95.8) 8/10 (80.0) 38/38 (100) 8/8 (100) 38/40 (95.0)
>3 mo ago 41/42 (97.6) 7/7 (100) 34/35 (97.1) 7/8 (87.5) 34/34 (100)
None stated 689/691 (99.7) 23/23 (100) 666/668 (99.7) 23/25 (92.0) 666/666 (100)

*LiPA, line probe assay; MTBC, Mycobacterium tuberculosis complex; AFB, acid-fast bacilli; PPV, positive predictive value; NPV, negative predictive value.

Main Article

1Current affiliation: University of Malaya, Kuala Lumpur, Malaysia

Page created: January 06, 2012
Page updated: January 06, 2012
Page reviewed: January 06, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.